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Abstracts

Physics 2: Delivery Technics including FLASH and Spot-Scanning Proton Arc
(SPARC)
PTCNA-0038
Assessing the interplay effect based on a precise machine-specific delivery
sequence and time for cyclotron accelerator proton therapy system
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Purpose: We proposed an experimental approach to build a precise machine-specific model for standard, volumetric, and
layer repainting delivery based on a cyclotron accelerator system. Then, we assessed the interplay effect using a 4D mobile
lung target phantom compared to a generic delivery sequence model from West German Proton Therapy Essen (WPE).
Methods: The machine delivery log files, from an IBA ProteusPLUSt system, were retrospectively analyzed to
quantitatively model energy layer switching time, spot switching time, and spot drill time for standard and volumetric repainting
delivery. To quantitatively evaluate the interplay effect, a series of digital thoracic 4DCT image sets were used. The interplay
effect was assessed based on the 4D dynamic dose accumulation method. Different delivery technique such as standard
delivery (n¼1), volumetric repainting delivery (n¼2,3,4) and layer repainting delivery (n¼2,3,5,25) were simulated based on the
machine-specific delivery sequence model and WPE model.
Results: The results showed that the WPE model’s spot delivery sequence deviated from the log file significantly compared
to the machine-specific model. Based on the treatment delivery calculation of a lung treatment plan with target size (65 mm3)
and layer repainting 25 times (n¼25), the difference is about 21.01%. Such a difference also resulted in different interplay
effects estimation between the two models even though both institutions used the same proton system from IBA and
calculated using the same 4DCT imaging set.
Conclusion: A precise machine-specific delivery sequence is highly recommended to ensure an accurate estimation of
mobile target treatment’s interplay effect.
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Purpose: To assess acute GI and GU toxicities of IMPT targeting prostate/seminal vesicles and pelvic lymph nodes for
prostate cancer
Methods: A prospective study (ClinicalTrials.gov: NCT02874014) evaluating moderately hypo-fractionated IMPT for highrisk (HR) or unfavorable intermediate-risk (UIR) prostate cancer accrued 56 patients. Prostate/seminal vesicles and pelvic
lymph nodes were treated simultaneously with 6750 and 4500 cGy RBE, respectively, in 25 daily fractions. All received
androgen deprivation therapy. Acute GI and GU toxicities were prospectively assessed, using 7 GI and 9 GU categories of
CTCAEv.4, at baseline, weekly during radiotherapy, and 3-month post-radiotherapy. Fisher exact tests were used for
comparisons of categorical data.
Results: Median age: 75 years. Median follow-up: 25 months. 55 patients (52: HR; 3: UIR) were available for acute toxicity
assessment. 62% and 2% experienced acute grade 1 and 2 GI toxicity, respectively. 65% and 35% had acute grade 1 and 2
GU toxicity, respectively. None had acute grade  3 GI or GU toxicity. The presence of baseline GI and GU symptoms was
associated with a greater likelihood of experiencing acute GI and GU toxicity, respectively (Table 1 and 2). Of 45 patients with
baseline GU symptoms, 44% experienced acute grade 2 GU toxicity, compared to only 10% among 10 with no baseline GU
symptoms (p¼0.07). Although acute grade 1 and 2 GI and GU toxicities were common during radiotherapy, most resolved at 3
months post-radiotherapy.
Conclusions: A moderately hypo-fractionated regimen of IMPT targeting prostate/seminal vesicles and pelvic lymph nodes
yielded very acceptable acute GI and GU toxicity.

